sharon sanders
Editor-in-Chief & President
Chinese Published Pneumococcus epidemiology and antibiotic research data
At 14:38 on March 23, 2009
Source: Sohu health
March 18, 2009 Bangkok message - in the "7th International antibacterial drugs and drug resistance Colloquium (ISAAR)" published by the Chinese side on the latest research data indicate that pneumococcal disease caused by bacteria strains are changing, and its to commonly used antibiotics (erythromycin and penicillin) resistance is increased.
In Beijing to a study conducted a survey in 1997 and 2000-2007 respiratory infections in children on pneumococcal serotypes 6A, 6B and 6C of the distribution. The study also assessed the antibiotics (erythromycin and penicillin) the effect of these strains.
The study collected 860 pneumococcal isolates, of which 109 (12.7%) showed 6 serogroups. One of the 6A, 6B and 6C, respectively, for type 62 (56.9%), 38 (34.9%) and 9 (8.2%). The results showed 6A, 6B and 6C serotypes the proportion between the years 1997-2007 at a downward trend (respectively 20.3% and 8.8%); The results also show that in China Pneumococcus serotype 6 of erythromycin resistance (increased to - Fla1 edit) 100%.
During the same period, serotype 19A isolates increased from 2000-2001, rose to 2.59 percent of the 2006-2007 20%, and serotype 19A in the penicillin non-susceptible strains in 2000-2001 increased from 3.92% 2006-2007 up to 26%.
Capital Medical University, Beijing, China subsidiary of Children's Hospital Professor Yang said: "These results suggest that pneumococcal disease caused by bacteria are evolutionary. Serotypes previously popular now not so popular, and previously effective antibiotics now have much effect. For cause Pneumococcus serotype disease as well as how the evolution of conventional understanding of the effectiveness of therapy will help us better cope with this disease. "
Pneumococcal disease all over the world took a year at around 1.6 million people's lives, there is one of one million are children under the age of 5. One of the highest incidence rates in 10 countries in Asia have five, respectively, are Bangladesh, China, India, Indonesia and Pakistan.
Pneumococcus has around 90 kinds of serotypes (strains). The main popular perfringens serotypes with age, time and geographical vary, but all over the world have also been found in common serotypes.
Pneumococcus higher incidence of disease and 7-valent pneumococcal conjugate vaccine (PVC7) demonstrated the effectiveness of prompted the World Health Organization (WHO) recommend that priority be PCV7 at all over the world included in the scope of each country's child immunization program. 3
The United States will be included in the PCV7 routine childhood immunization program, with the approval of the use of the vaccine compared to the previous data, the United States in children under 5 years of age covered by the vaccine serotypes caused the incidence of pneumococcal disease decreased by 98%. 3 In addition, over the age of 50 unvaccinated adults, PCV7 coverage of seven kinds of pneumococcal serotypes caused by the incidence has declined 55 percent.
After the introduction of PCV7 covered by PCV7 pneumococcal antibiotic resistance is also decreased. After the use of PCV7 in the United States vaccinated children caused by penicillin-resistant strains of invasive pneumococcal disease reduces 80%. It is important that in other age groups, drug penicillin-resistant strains caused by invasive pneumococcal disease incidence declined. 5
More recently, the pneumococcal serotype 19A (PCV7 not covered) in the epidemic rise in many regions of the world, and often there is resistance to antibiotics.
13-valent pneumococcal conjugate vaccine (PCV13) is a research and development phase of the vaccine are, including 13 kinds and severity of pneumococcal disease the most common serotypes, PREVENAR (Prevenar), including one of seven kinds of serotypes (4 , 6B, 9V, 14,18 C, 19F and 23F); other six kinds of serotypes (1,3,5,6 A, 7F and 19A) with a higher incidence of other invasive pneumococcal disease-related. In 2008 Wyeth began a 13-valent pneumococcal vaccine in the global scope of application for registration. Wyeth is expected to finish the first quarter of 2009 at the United States application for registration. 13-valent pneumococcal vaccine is also a global Phase III clinical trials of adult studies, is expected to start in 2010 the application for registration.
"Since listing, the PREVENAR has been at the field of public health have a significant impact, greatly reducing the common invasive pneumococcal disease incidence. Study of 13-valent pneumococcal conjugate vaccine will expand the scope of protection is expected to cover all over the world 93% of infants and children, invasive pneumococcal disease. "Wyeth Pharmaceuticals vaccine R & D department, executive vice president, Dr. Emilio Emini said.
http://health.sohu.com/20090323/n262957386.shtml
At 14:38 on March 23, 2009
Source: Sohu health
March 18, 2009 Bangkok message - in the "7th International antibacterial drugs and drug resistance Colloquium (ISAAR)" published by the Chinese side on the latest research data indicate that pneumococcal disease caused by bacteria strains are changing, and its to commonly used antibiotics (erythromycin and penicillin) resistance is increased.
In Beijing to a study conducted a survey in 1997 and 2000-2007 respiratory infections in children on pneumococcal serotypes 6A, 6B and 6C of the distribution. The study also assessed the antibiotics (erythromycin and penicillin) the effect of these strains.
The study collected 860 pneumococcal isolates, of which 109 (12.7%) showed 6 serogroups. One of the 6A, 6B and 6C, respectively, for type 62 (56.9%), 38 (34.9%) and 9 (8.2%). The results showed 6A, 6B and 6C serotypes the proportion between the years 1997-2007 at a downward trend (respectively 20.3% and 8.8%); The results also show that in China Pneumococcus serotype 6 of erythromycin resistance (increased to - Fla1 edit) 100%.
During the same period, serotype 19A isolates increased from 2000-2001, rose to 2.59 percent of the 2006-2007 20%, and serotype 19A in the penicillin non-susceptible strains in 2000-2001 increased from 3.92% 2006-2007 up to 26%.
Capital Medical University, Beijing, China subsidiary of Children's Hospital Professor Yang said: "These results suggest that pneumococcal disease caused by bacteria are evolutionary. Serotypes previously popular now not so popular, and previously effective antibiotics now have much effect. For cause Pneumococcus serotype disease as well as how the evolution of conventional understanding of the effectiveness of therapy will help us better cope with this disease. "
Pneumococcal disease all over the world took a year at around 1.6 million people's lives, there is one of one million are children under the age of 5. One of the highest incidence rates in 10 countries in Asia have five, respectively, are Bangladesh, China, India, Indonesia and Pakistan.
Pneumococcus has around 90 kinds of serotypes (strains). The main popular perfringens serotypes with age, time and geographical vary, but all over the world have also been found in common serotypes.
Pneumococcus higher incidence of disease and 7-valent pneumococcal conjugate vaccine (PVC7) demonstrated the effectiveness of prompted the World Health Organization (WHO) recommend that priority be PCV7 at all over the world included in the scope of each country's child immunization program. 3
The United States will be included in the PCV7 routine childhood immunization program, with the approval of the use of the vaccine compared to the previous data, the United States in children under 5 years of age covered by the vaccine serotypes caused the incidence of pneumococcal disease decreased by 98%. 3 In addition, over the age of 50 unvaccinated adults, PCV7 coverage of seven kinds of pneumococcal serotypes caused by the incidence has declined 55 percent.
After the introduction of PCV7 covered by PCV7 pneumococcal antibiotic resistance is also decreased. After the use of PCV7 in the United States vaccinated children caused by penicillin-resistant strains of invasive pneumococcal disease reduces 80%. It is important that in other age groups, drug penicillin-resistant strains caused by invasive pneumococcal disease incidence declined. 5
More recently, the pneumococcal serotype 19A (PCV7 not covered) in the epidemic rise in many regions of the world, and often there is resistance to antibiotics.
13-valent pneumococcal conjugate vaccine (PCV13) is a research and development phase of the vaccine are, including 13 kinds and severity of pneumococcal disease the most common serotypes, PREVENAR (Prevenar), including one of seven kinds of serotypes (4 , 6B, 9V, 14,18 C, 19F and 23F); other six kinds of serotypes (1,3,5,6 A, 7F and 19A) with a higher incidence of other invasive pneumococcal disease-related. In 2008 Wyeth began a 13-valent pneumococcal vaccine in the global scope of application for registration. Wyeth is expected to finish the first quarter of 2009 at the United States application for registration. 13-valent pneumococcal vaccine is also a global Phase III clinical trials of adult studies, is expected to start in 2010 the application for registration.
"Since listing, the PREVENAR has been at the field of public health have a significant impact, greatly reducing the common invasive pneumococcal disease incidence. Study of 13-valent pneumococcal conjugate vaccine will expand the scope of protection is expected to cover all over the world 93% of infants and children, invasive pneumococcal disease. "Wyeth Pharmaceuticals vaccine R & D department, executive vice president, Dr. Emilio Emini said.
http://health.sohu.com/20090323/n262957386.shtml